Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates

Yizhou Dong, Kevin T. Love, J. Robert Dorkin, Sasilada Sirirungruang, Yunlong Zhang, Delai Chen, Roman L. Bogorad, Hao Yin, Yi Chen, Arturo J. Vegas, Christopher A. Alabi, Gaurav Sahay, Karsten T. Olejnik, Weiheng Wang, Avi Schroeder, Abigail K R Lytton-Jean, Daniel J. Siegwart, Akin Akinc, Carmen Barnes, Scott A. BarrosMary Carioto, Kevin Fitzgerald, Julia Hettinger, Varun Kumar, Tatiana I. Novobrantseva, June Qin, William Querbes, Victor Koteliansky, Robert Langer, Daniel G. Anderson

Research output: Contribution to journalArticle

168 Citations (Scopus)

Abstract

siRNA therapeutics have promise for the treatment of a wide range of genetic disorders. Motivated by lipoproteins, we report lipopeptide nanoparticles as potent and selective siRNA carriers with a wide therapeutic index. Lead material cKK-E12 showed potent silencing effects in mice (ED50 ̃ 0.002 mg/kg), rats (ED50 < 0.01 mg/kg), and nonhuman primates (over 95% silencing at 0.3 mg/kg). Apolipoprotein E plays a significant role in the potency of cKK-E12 both in vitro and in vivo. cKK-E12 was highly selective toward liver parenchymal cell in vivo, with orders of magnitude lower doses needed to silence in hepatocytes compared with endothelial cells and immune cells in different organs. Toxicity studies showed that cKK-E12 was well tolerated in rats at a dose of 1 mg/kg (over 100-fold higher than the ED50). To our knowledge, this is the most efficacious and selective nonviral siRNA delivery system for gene silencing in hepatocytes reported to date.

Original languageEnglish (US)
Pages (from-to)3955-3960
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume111
Issue number11
DOIs
StatePublished - Mar 18 2014

Fingerprint

Lipopeptides
Nanoparticles
Primates
Small Interfering RNA
Rodentia
Hepatocytes
Inborn Genetic Diseases
Gene Silencing
Apolipoproteins E
Lipoproteins
Endothelial Cells
Liver
Therapeutics

Keywords

  • Lipopeptide nanomaterials
  • Liver genetic disorders
  • Tissue and cell specificity
  • Translational research

ASJC Scopus subject areas

  • General

Cite this

Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates. / Dong, Yizhou; Love, Kevin T.; Dorkin, J. Robert; Sirirungruang, Sasilada; Zhang, Yunlong; Chen, Delai; Bogorad, Roman L.; Yin, Hao; Chen, Yi; Vegas, Arturo J.; Alabi, Christopher A.; Sahay, Gaurav; Olejnik, Karsten T.; Wang, Weiheng; Schroeder, Avi; Lytton-Jean, Abigail K R; Siegwart, Daniel J.; Akinc, Akin; Barnes, Carmen; Barros, Scott A.; Carioto, Mary; Fitzgerald, Kevin; Hettinger, Julia; Kumar, Varun; Novobrantseva, Tatiana I.; Qin, June; Querbes, William; Koteliansky, Victor; Langer, Robert; Anderson, Daniel G.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 111, No. 11, 18.03.2014, p. 3955-3960.

Research output: Contribution to journalArticle

Dong, Y, Love, KT, Dorkin, JR, Sirirungruang, S, Zhang, Y, Chen, D, Bogorad, RL, Yin, H, Chen, Y, Vegas, AJ, Alabi, CA, Sahay, G, Olejnik, KT, Wang, W, Schroeder, A, Lytton-Jean, AKR, Siegwart, DJ, Akinc, A, Barnes, C, Barros, SA, Carioto, M, Fitzgerald, K, Hettinger, J, Kumar, V, Novobrantseva, TI, Qin, J, Querbes, W, Koteliansky, V, Langer, R & Anderson, DG 2014, 'Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates', Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 11, pp. 3955-3960. https://doi.org/10.1073/pnas.1322937111
Dong, Yizhou ; Love, Kevin T. ; Dorkin, J. Robert ; Sirirungruang, Sasilada ; Zhang, Yunlong ; Chen, Delai ; Bogorad, Roman L. ; Yin, Hao ; Chen, Yi ; Vegas, Arturo J. ; Alabi, Christopher A. ; Sahay, Gaurav ; Olejnik, Karsten T. ; Wang, Weiheng ; Schroeder, Avi ; Lytton-Jean, Abigail K R ; Siegwart, Daniel J. ; Akinc, Akin ; Barnes, Carmen ; Barros, Scott A. ; Carioto, Mary ; Fitzgerald, Kevin ; Hettinger, Julia ; Kumar, Varun ; Novobrantseva, Tatiana I. ; Qin, June ; Querbes, William ; Koteliansky, Victor ; Langer, Robert ; Anderson, Daniel G. / Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates. In: Proceedings of the National Academy of Sciences of the United States of America. 2014 ; Vol. 111, No. 11. pp. 3955-3960.
@article{be9d44ea43db4181a3a34938bdc9c3fe,
title = "Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates",
abstract = "siRNA therapeutics have promise for the treatment of a wide range of genetic disorders. Motivated by lipoproteins, we report lipopeptide nanoparticles as potent and selective siRNA carriers with a wide therapeutic index. Lead material cKK-E12 showed potent silencing effects in mice (ED50 ̃ 0.002 mg/kg), rats (ED50 < 0.01 mg/kg), and nonhuman primates (over 95{\%} silencing at 0.3 mg/kg). Apolipoprotein E plays a significant role in the potency of cKK-E12 both in vitro and in vivo. cKK-E12 was highly selective toward liver parenchymal cell in vivo, with orders of magnitude lower doses needed to silence in hepatocytes compared with endothelial cells and immune cells in different organs. Toxicity studies showed that cKK-E12 was well tolerated in rats at a dose of 1 mg/kg (over 100-fold higher than the ED50). To our knowledge, this is the most efficacious and selective nonviral siRNA delivery system for gene silencing in hepatocytes reported to date.",
keywords = "Lipopeptide nanomaterials, Liver genetic disorders, Tissue and cell specificity, Translational research",
author = "Yizhou Dong and Love, {Kevin T.} and Dorkin, {J. Robert} and Sasilada Sirirungruang and Yunlong Zhang and Delai Chen and Bogorad, {Roman L.} and Hao Yin and Yi Chen and Vegas, {Arturo J.} and Alabi, {Christopher A.} and Gaurav Sahay and Olejnik, {Karsten T.} and Weiheng Wang and Avi Schroeder and Lytton-Jean, {Abigail K R} and Siegwart, {Daniel J.} and Akin Akinc and Carmen Barnes and Barros, {Scott A.} and Mary Carioto and Kevin Fitzgerald and Julia Hettinger and Varun Kumar and Novobrantseva, {Tatiana I.} and June Qin and William Querbes and Victor Koteliansky and Robert Langer and Anderson, {Daniel G.}",
year = "2014",
month = "3",
day = "18",
doi = "10.1073/pnas.1322937111",
language = "English (US)",
volume = "111",
pages = "3955--3960",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "11",

}

TY - JOUR

T1 - Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates

AU - Dong, Yizhou

AU - Love, Kevin T.

AU - Dorkin, J. Robert

AU - Sirirungruang, Sasilada

AU - Zhang, Yunlong

AU - Chen, Delai

AU - Bogorad, Roman L.

AU - Yin, Hao

AU - Chen, Yi

AU - Vegas, Arturo J.

AU - Alabi, Christopher A.

AU - Sahay, Gaurav

AU - Olejnik, Karsten T.

AU - Wang, Weiheng

AU - Schroeder, Avi

AU - Lytton-Jean, Abigail K R

AU - Siegwart, Daniel J.

AU - Akinc, Akin

AU - Barnes, Carmen

AU - Barros, Scott A.

AU - Carioto, Mary

AU - Fitzgerald, Kevin

AU - Hettinger, Julia

AU - Kumar, Varun

AU - Novobrantseva, Tatiana I.

AU - Qin, June

AU - Querbes, William

AU - Koteliansky, Victor

AU - Langer, Robert

AU - Anderson, Daniel G.

PY - 2014/3/18

Y1 - 2014/3/18

N2 - siRNA therapeutics have promise for the treatment of a wide range of genetic disorders. Motivated by lipoproteins, we report lipopeptide nanoparticles as potent and selective siRNA carriers with a wide therapeutic index. Lead material cKK-E12 showed potent silencing effects in mice (ED50 ̃ 0.002 mg/kg), rats (ED50 < 0.01 mg/kg), and nonhuman primates (over 95% silencing at 0.3 mg/kg). Apolipoprotein E plays a significant role in the potency of cKK-E12 both in vitro and in vivo. cKK-E12 was highly selective toward liver parenchymal cell in vivo, with orders of magnitude lower doses needed to silence in hepatocytes compared with endothelial cells and immune cells in different organs. Toxicity studies showed that cKK-E12 was well tolerated in rats at a dose of 1 mg/kg (over 100-fold higher than the ED50). To our knowledge, this is the most efficacious and selective nonviral siRNA delivery system for gene silencing in hepatocytes reported to date.

AB - siRNA therapeutics have promise for the treatment of a wide range of genetic disorders. Motivated by lipoproteins, we report lipopeptide nanoparticles as potent and selective siRNA carriers with a wide therapeutic index. Lead material cKK-E12 showed potent silencing effects in mice (ED50 ̃ 0.002 mg/kg), rats (ED50 < 0.01 mg/kg), and nonhuman primates (over 95% silencing at 0.3 mg/kg). Apolipoprotein E plays a significant role in the potency of cKK-E12 both in vitro and in vivo. cKK-E12 was highly selective toward liver parenchymal cell in vivo, with orders of magnitude lower doses needed to silence in hepatocytes compared with endothelial cells and immune cells in different organs. Toxicity studies showed that cKK-E12 was well tolerated in rats at a dose of 1 mg/kg (over 100-fold higher than the ED50). To our knowledge, this is the most efficacious and selective nonviral siRNA delivery system for gene silencing in hepatocytes reported to date.

KW - Lipopeptide nanomaterials

KW - Liver genetic disorders

KW - Tissue and cell specificity

KW - Translational research

UR - http://www.scopus.com/inward/record.url?scp=84896519424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896519424&partnerID=8YFLogxK

U2 - 10.1073/pnas.1322937111

DO - 10.1073/pnas.1322937111

M3 - Article

C2 - 24516150

AN - SCOPUS:84896519424

VL - 111

SP - 3955

EP - 3960

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 11

ER -